ArticleEuropean journal of haematology2026
Prognostic Impact of Chromosome 1q Gain/Amplification in Multiple Myeloma Treated With Daratumumab-Based Regimens.
Article in European journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gain/amplification of chromosome arm 1q (+1q) is among the most frequent cytogenetic abnormalities (CAs) in multiple myeloma (MM), and a recognized marker of poor prognosis, now integrated into modern risk stratification systems. The advent of anti-CD38 monoclonal antibodies, particularly daratumumab, has significantly improved outcomes. However, the prognostic impact of +1q under daratumumab-based treatments (DBTs) remains uncertain, since pivotal trials rarely reported +1q-specific outcomes, and available real-world data are limited and inconsistent. We conducted a single-center retrospective study of 174 MM patients treated with DBTs between 2018 and 2023 to evaluate the prognostic effect of +1q. By FISH cytogenetic assessment we identified standard-risk (SR), isolated +1q, +1q plus additional high-risk CAs (+1q + HiRCAs), and non-1q HiRCAs groups. The primary endpoint was progression-free survival (PFS); secondary endpoints were time to next treatment (TTNT) and overall survival (OS). Median age was 72.0 years, median line of DBT administration was 2, and 125 patients (71.8%) received daratumumab-lenalidomide-dexamethasone (DaraRd). Cytogenetic data were available for 92 patients (52.9%): 43 SR, 11 non-1q HiRCAs, 18 isolated +1q and 20 +1q + HiRCAs. After a median follow-up of 30.7 months, isolated +1q was associated with significantly shorter PFS (HR 4.77, 95% CI: 1.68-13.53) and TTNT (HR 3.83, 95% CI: 1.33-11.09) versus SR, while +1q + HiRCAs had the worst outcomes across all endpoints (PFS HR 7.67; TTNT HR 5.81; OS HR 6.03). Multivariate analysis confirmed isolated +1q as an independent predictor of inferior PFS (HR 4.56, 95% CI: 1.61-12.95) and TTNT (HR 3.64, 95% CI: 1.26-10.55), with +1q + HiRCAs conferring the highest risks on all outcomes (PFS HR 8.36; TTNT HR 6.37; OS HR 6.18). Findings were consistent in the DaraRd subgroup. These findings demonstrate that +1q retains prognostic significance in the era of DBTs. Isolated +1q remains an independent factor of adverse prognosis, further worsened by co-existing HiRCAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.